Cancer Research UK

Quick facts

Phase 3 pipeline

• releasing hormone agonist therapy · Oncology
  Releasing hormone agonist therapy works by mimicking the action of natural hormones to stimulate the release of other hormones.

Phase 2 pipeline

• Trastuzumab in combination with pertuzumab
• Vemurafenib in combination with cobimetinib

Phase 1 pipeline

• [124I]meta-Iodobenzylguanidine
• ALETA-001
• AST-VAC2
• AT13148
• BI-1206 single agent expansion phase
• BT1718
• DI-B4
• glioblastoma multiforme multipeptide vaccine IMA950
• HMBD-001
• HMBD-001 and enzalutamide
• HTL0039732 Capsules
• HTL0039732 Capsules and atezolizumab infusion
• LY3143921 hydrate
• MOv18 IgE
• multikinase inhibitor AT9283
• Notch signaling pathway inhibitor MK0752
• TT-702
• UCB4594
• Vandetanib, Selumetinib

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cancer Research UK portfolio CI brief
• Cancer Research UK pipeline updates RSS